Description
Zanidatamabis indicated for the treatment of adults with previously treated, unresectable or metastatic HER2-positive (IHC 3+) biliary tract cancer, as detected by an FDA-approved test.
The most common adverse reactions include diarrhea, infusion-related reaction, abdominal pain, and fatigue.
Zanidatamab was approved for medical use in the United States in November 2024. The US Food and Drug Administration (FDA) considers it to be a first-in-class medication.
ZIIHERA® (zanidatamab-hrii) for injection, for intravenous use. Initial U.S. Approval: 2024
See full prescribing information : Click Here
Get Access To Ziihera (zanidatamab-hrii) and Oral Suspension In India On Request
Brand Name “Ziihera” or Generic Name “zanidatamab-hrii” can be imported for personal use under “Named Patient Program” treatment in Delhi, Kolkata, Surat, Jaipur, Noida, Gurgaon (Gurugram), Punjab, Chandigarh, Bhubaneswar, Arunachal Pradesh, Assam, Manipur, Meghalaya, Mizoram, Nagaland, Tripura and Sikkim, Noida, Kanpur, Lucknow, Dehradun, Shimla, Ahmedabad, Jodhpur, Mumbai, Jaipur, Aurangabad, Pune, Bangalore, Hyderabad, Chennai, Visakhapatnam, Coimbatore, Andhra Pradesh, Karnataka, Kerala, Lakshadweep, Puducherry, Tamil Nadu, Telangana, India. Contact us at support@southdelhipharma.net, southdelhipharma@gmail.com or you can call at 9891296838 or WhatsApp at 9891296838
